Tobacco nicotine promotes TRAIL resistance in lung cancer through SNHG5

Exp Ther Med. 2023 Feb 10;25(3):131. doi: 10.3892/etm.2023.11830. eCollection 2023 Mar.

Abstract

Tobacco nicotine use is carcinogenic and a well-known risk factor for lung cancer. However, whether tobacco nicotine can induce drug resistance in lung cancer is not clear. The objective of the present study was to identify the TNF-related apoptosis-inducing ligand (TRAIL) resistance of long noncoding RNAs (lncRNAs) that are differentially expressed in smokers and nonsmokers with lung cancer. The results suggested that the nicotine upregulated small nucleolar RNA host gene 5 (SNHG5) and markedly decreased the levels of cleaved caspase-3. The present study found that cytoplasm lncRNA SNHG5 overexpression was associated with TRAIL resistance in lung cancer and that SNHG5 can interact with X-linked inhibitor of apoptosis protein to promote TRAIL resistance. Therefore, nicotine promoted TRAIL resistance in lung cancer through SNHG5/X-linked inhibitor of apoptosis protein.

Keywords: TNF-related apoptosis-inducing ligand resistance; apoptosis; lung cancer; small nucleolar RNA host gene 5.

Grants and funding

Funding: This study was supported by a grant from the Anhui Medical University Project Fund (grant no. 2021xkj188).